News

Researchers from the University at Buffalo revealed their findings on Wednesday morning from a study focusing on people living with multiple sclerosis both here in Buffalo and in Boston, Massachusetts.

A UB research program that is investigating what causes some people with multiple sclerosis to experience severe and aggressive disease is beginning to shed light on how their disease differs from those with mild to moderate MS.

Initial findings from UB’s Comprehensive Assessment of Severely Affected MS (CASA-MS), reveal that some of the so-called “gold standards” of MS monitoring are inadequate for patients with severe disease and that novel methods of assessing these people can be more effective

What is the role of AI in multiple sclerosis (MS) management? Is this technology poised to replace the jobs of neurologists and neuroradiologists?

A team led by a BNAC faculty member, Junghun Cho, Assistant Professor in Biomedical Engineering and Neurology, has been awarded a five-year, $1.77 million Research Project Grant (R01) from the National Institutes of Health.

The new technology could expand access to medical imaging; improve treatment for multiple sclerosis, Alzheimer's disease, and other neurological disorders.

Niels Bergsland is an Assistant Professor of Neurology at the State University of New York at Buffalo and serves as the Integration Director in BNAC and is part of BNAC’s leadership team.

A recent study conducted by a BNAC research team led by Jack Reeves, a Ph.D. candidate, showed that an imaging marker called “paramagnetic rim lesions” predicts greater multiple sclerosis (MS) related disability progression and clinical relapse frequency over 10 years.

Listen as Dr. Dejan Jakimovski joins the ReachMD radio program discussing his latest study and findings regarding severely affected people with multiple sclerosis.

The Buffalo Neuroimaging Analysis Center (BNAC) enjoyed the spotlight at the recent European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023 where its researchers were recognized for an unprecedented array of publications that are shaping the field of neuroimaging in multiple sclerosis (pwMS) and related disorders.

Recent advancements in multiple sclerosis (MS) research, including improved diagnostic criteria and novel MRI techniques, have been highlighted in a new Lancet paper by researchers from the Buffalo Neuroimaging Analysis Center (BNAC) and the Jacobs MS Center for Treatment and Research.

On October 5th Buffalo Neuroimaging Analysis Center celebrated the opening of its new headquarters located at the University at Buffalo's Downtown Gateway Building.

At MSMilan 2023, the joint ECTRIMS-ACTRIMS meeting, held October 11-13, in Milan, Italy, Tom Fuchs, MD, PhD, presented in a scientific session on the effects of MS on cognition, including cognitive progression independent of relapse activity.

Buffalo Neuroimaging Analysis Center presents the Grand Opening of our New Offices on October 5th, 2023.

The massive 5.5-ton Philips MR 7700 that was installed in June in the Center for Biomedical Imaging (CBI) in UB’s Clinical and Translational Research Center (CTRC) is now operational.

The June delivery of a Philips MR 7700 to the Clinical and Translational Research Center (CTRC) was called “a major advance in our translational research environment” by University at Buffalo Clinical and Translational Science Institute (CTSI) Director Timothy F. Murphy, MD. And for researchers at the University at Buffalo and Buffalo Translational Consortium, the impact of the 5-ton, 3-Tesla magnetic resonance imaging (MRI) scanner looks to be momentous.

Associate Professor of Neurology, Radiology, and Biomedical Engineering at the University at Buffalo, Ferdinand Schweser, Ph.D, is a member of BNAC’s leadership team and continues to make significant contributions to the field of neuroimaging. His expertise lies in the MRI technique called quantitative susceptibility mapping (QSM) and its application in studying the relationship between brain iron and MS.

Retinal nerve fiber thickness may serve as a potential biomarker for cognitive impairment in people with MS, possibly predicting future cognitive decline.